GAO 12 115 Prescription Pain Reliever Abuse Agencies

Gao 12 115 Prescription Pain Reliever Abuse Agencies-Free PDF

  • Date:27 Nov 2019
  • Views:30
  • Downloads:0
  • Pages:73
  • Size:1.40 MB

Share Pdf : Gao 12 115 Prescription Pain Reliever Abuse Agencies

Download and Preview : Gao 12 115 Prescription Pain Reliever Abuse Agencies


Report CopyRight/DMCA Form For : Gao 12 115 Prescription Pain Reliever Abuse Agencies


Transcription:

December 2011,PRESCRIPTION PAIN RELIEVER ABUSE,Agencies Have Begun Coordinating Education. Efforts but Need to Assess Effectiveness,Highlights of GAO 12 115 a report to. congressional requesters,Why GAO Did This Study What GAO Found. The Centers for Disease Control and Key measures of prescription pain reliever abuse and misuse increased from. Prevention has declared that the 2003 to 2009 The largest increases were in measures of adverse health. United States is in the midst of an consequences such as emergency department visits substance abuse treatment. epidemic of prescription drug overdose admissions and unintentional overdose deaths though increases were not. deaths with deaths associated with consistent across all measures Federal officials suggested that increasing. prescription pain relievers of particular availability of prescription pain relievers and high risk behaviors by those who. concern To address this issue federal abuse or misuse the drugs such as combining prescription pain relievers with. agencies are raising awareness by other drugs or alcohol likely contributed to the rise in adverse health. educating prescribers and the general, consequences though data about the reasons for the increases are limited. public In response to your request, GAO 1 described recent national The Food and Drug Administration FDA the National Institutes of Health NIH.
trends in prescription pain reliever and the Substance Abuse and Mental Health Services Administration SAMHSA. abuse and misuse 2 described how use a variety of strategies to educate prescribers about issues related to. federal agencies are educating prescription pain reliever abuse and misuse but officials told us that more. prescribers 3 assessed the extent to education is needed The strategies used include developing continuing medical. which federal agencies follow key education programs requiring training and certification in order to prescribe. practices for developing public certain drugs and developing curriculum resources for future prescribers The. education efforts and 4 identified Office of National Drug Control Policy ONDCP is working to develop a. educational efforts that use similar, legislative proposal to require education for prescribers registering with the Drug. strategies and assessed how agencies, Enforcement Administration DEA to prescribe controlled substances Officials. coordinate those efforts, from some agencies said such a requirement would ensure all prescribers were. GAO interviewed officials and reviewed starting from the same baseline of knowledge. documents and websites from seven, agencies involved in federal drug In their efforts to educate the public about prescription pain reliever abuse and. control efforts and analyzed the most misuse DEA FDA NIH ONDCP and SAMHSA used almost all of the key. recent data from several data sources practices for developing their consumer education efforts Agencies varied in how. related to prescription pain reliever they used the key practices when developing these efforts which varied in size. abuse and misuse GAO also scope and duration All agencies established metrics to monitor the. assessed the development of public implementation and functional elements of their educational efforts but only two. education efforts and federal agencies have established or are planning to establish metrics to assess the. coordination efforts against key impact of their efforts on audiences knowledge attitudes and behavior Without. practices from prior GAO work outcome evaluations federal agencies have limited knowledge of how effective. their efforts are in achieving their goals in this case reducing prescription pain. What GAO Recommends reliever abuse and misuse,GAO recommends that the Director of.
Among federal initiatives to educate prescribers and the public about prescription. ONDCP establish outcome metrics and, pain reliever abuse and misuse GAO found several instances of agencies. implement a plan to evaluate proposed, educational efforts and ensure that engaging in similar efforts directed at similar target audiences and using similar. agencies share lessons learned among mediums Officials said that these similarities in public education efforts are. similar efforts ONDCP did not beneficial in addressing prescription drug abuse and misuse because having. explicitly agree or disagree with GAO s multiple reinforcing messages about the same subject is valuable in public. recommendations but noted that it will health communications and because federal agencies provide slightly different. continue to work for improved perspectives on the issues surrounding prescription drug abuse and misuse. coordination of educational efforts and Likewise the prescriber education programs GAO identified though similar are. evaluation of outcomes different in content and focus Though these similar programs have the potential. to be duplicative if not effectively coordinated federal agencies have recently. View GAO 12 115 For more information begun to coordinate their educational efforts Nevertheless federal agencies. contact Marcia Crosse at 202 512 7114 or have missed opportunities to share lessons learned and pool resources among. crossem gao gov,similar education efforts,United States Government Accountability Office. Background 5, Key Measures of Prescription Pain Reliever Abuse and Misuse. Have Increased Nationwide 11, Federal Agencies Are Using Various Strategies to Educate.
Prescribers about Issues Related to Prescription Pain Reliever. Abuse and Misuse 16, Federal Agencies Generally Followed Key Practices When. Developing Public Education Efforts 20, Federal Agencies Have Begun Coordinating Similar Public and. Prescriber Education Efforts but Have Missed Opportunities to. Share Resources 26,Conclusions 38,Recommendations for Executive Action 39. Agency Comments and Our Evaluation 39, Appendix I Abuse Deterrent Formulations of Prescription Pain Relievers 41. Appendix II DEA Quotas for Controlled Substances 46. Appendix III Objectives Scope and Methodology 52,Appendix IV Public Education Programs 60.
Appendix V Data from Key Measures of Prescription Pain Reliever Abuse. and Misuse 61, Appendix VI Comments from the Office of National Drug Control Policy 65. Appendix VII GAO Contact and Staff Acknowledgments 66. Page i GAO 12 115 Prescription Pain Reliever Abuse. Related GAO Products 67, Table 1 Public Education Efforts about Prescription Pain Reliever. Abuse and Misuse 27, Table 2 Efforts to Educate Prescribers about Issues Related to. Prescription Pain Reliever Abuse and Misuse 33, Table 3 Key Practices for Developing Public Education Efforts 58. Table 4 Summary of Federal Efforts to Educate the General Public. about Prescription Pain Reliever Abuse and Misuse 60. Table 5 Estimated Number of Emergency Department Visits. Related to Abuse and Misuse of Prescription Pain, Relievers by Age Groups with Confidence Intervals 2004.
Table 6 Number of Admissions to Substance Abuse Treatment. Facilities for Prescription Pain Reliever Abuse and Misuse. by Age Groups 2003 2009 63, Table 7 Number of Unintentional Overdose Deaths Involving. Prescription Pain Relievers by Age Groups 2003 2008 63. Table 8 Estimated Number of Individuals Who Reported Abusing. or Misusing Prescription Pain Relievers in the Past Year by. Age Groups with Confidence Intervals 2003 2009 in,Thousands 64. Figure 1 Measures of Adverse Health Consequences Related to. Abuse and Misuse of Prescription Pain Relievers among. the U S Population Aged 12 and Older 2003 to 2009 12. Figure 2 Agencies Use of Key Practices for Developing Public. Education Efforts 22,Figure 3 ONDCP and NIH Teen Websites 29. Figure 4 DEA Teen Website 30, Page ii GAO 12 115 Prescription Pain Reliever Abuse. Abbreviations,APQ aggregate production quota,CDC Centers for Disease Control and Prevention.
CE continuing education,CME continuing medical education. DAWN Drug Abuse Warning Network,DEA Drug Enforcement Administration. FDA Food and Drug Administration,HHS Department of Health and Human Services. HRSA Health Resources and Services Administration,NIDA National Institute on Drug Abuse. NIH National Institutes of Health,NSDUH National Survey on Drug Use and Health.
NVSS National Vital Statistics System,ONDCP Office of National Drug Control Policy. REMS Risk Evaluation and Mitigation Strategy,SAMHSA Substance Abuse and Mental Health Services. Administration,TEDS Treatment Episode Data Set, This is a work of the U S government and is not subject to copyright protection in the. United States The published product may be reproduced and distributed in its entirety. without further permission from GAO However because this work may contain. copyrighted images or other material permission from the copyright holder may be. necessary if you wish to reproduce this material separately. Page iii GAO 12 115 Prescription Pain Reliever Abuse. United States Government Accountability Office,Washington DC 20548. December 22 2011,The Honorable Darrell Issa,Committee on Oversight and Government Reform.
House of Representatives,The Honorable Mary Bono Mack. House of Representatives,The Honorable Edolphus Towns. House of Representatives, The Centers for Disease Control and Prevention CDC has declared that. the United States is in the midst of an epidemic of prescription drug. overdose deaths with such drugs involved in more overdose deaths than. those involving heroin and cocaine combined Further according to CDC. recent increases in prescription drug overdose deaths overall are largely. driven by deaths associated with prescription pain relievers which include. such drugs as OxyContin or Vicodin among others In 2009 an. estimated 12 4 million Americans reported using a prescription pain. reliever in the past year without a prescription of their own or simply for. the experience or feeling the drug caused according to the National. Survey on Drug Use and Health NSDUH Seventy percent of these. people reported that they got the drug from a friend or family member. while another 19 percent got the drug from a doctor 1 Although specific. regions of the country have been severely affected by this problem. recent media reports from across the United States suggest it is now a. national issue, Multiple federal agencies have responsibility for addressing the abuse. and misuse of prescription pain relievers through prevention treatment. According to NSDUH data from 2009 17 percent of these people reported that they got. the drug from one doctor and 2 percent reported that they got the drug from more than. one doctor, Page 1 GAO 12 115 Prescription Pain Reliever Abuse.
and enforcement activities 2 3 The Office of National Drug Control Policy. ONDCP assists in setting national drug control priorities and helps to. coordinate federal drug control efforts One prevention activity ONDCP. has identified as a focus area is raising awareness of the problem of. prescription drug abuse and misuse through the education of parents. youth patients and health care providers Accordingly the Drug. Enforcement Administration DEA the Food and Drug Administration. FDA the Health Resources and Services Administration HRSA the. National Institutes of Health s NIH National Institute on Drug Abuse. NIDA the Substance Abuse and Mental Health Services Administration. SAMHSA and ONDCP are engaged in various activities for educating. the public and health care providers who prescribe pain relievers about. issues related to abuse and misuse of these drugs These federal. agencies and ONDCP hereinafter collectively referred to as federal. agencies have assisted in developing and implementing strategies. specifically focused on preventing the inappropriate use of prescription. pain relievers since the early 2000s and our prior reports have. documented some of their efforts 4, You asked us to update our prior work on OxyContin to reflect changes in. oxycodone abuse trends and efforts aimed at stemming prescription drug. abuse since our 2003 report In response to that request we 1 describe. recent national trends in prescription pain reliever abuse and misuse. In this report the term prescription pain relievers refers to a class of pain relievers. known as opioid analgesics While multiple classes of pain relievers are used in the United. States opioid analgesics such as fentanyl hydrocodone methadone morphine and. oxycodone are the most commonly abused and misused pain relievers In addition to. relieving pain they can cause feelings of euphoria or a sense of well being among some. people who take them which may lead to their abuse and misuse. No standard definitions of prescription pain reliever abuse or prescription pain reliever. misuse are used by the federal agencies dealing with these issues In this report we use. the term abuse and misuse to collectively refer to the three types of inappropriate use. most often included in the agencies definitions using a prescription pain reliever with the. intent to get high with or without a prescription of one s own using a prescription pain. reliever for pain relief but without a prescription of one s own or using a prescription pain. reliever for pain relief with a prescription of one s own but in ways other than as. prescribed such as by taking more than prescribed,GAO Metha. Prescription Pain Reliever Abuse and Misuse 33 Table 3 Key Practices for Developing Public Education Efforts 58 Table 4 Summary of Federal Efforts to Educate the General Public about Prescription Pain Reliever Abuse and Misuse 60 Table 5 Estimated Number of Emergency Department Visits Related to Abuse and Misuse of Prescription Pain

Related Books